Serina Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights
On track for first patient dosing of SER-252 in Phase 1b clinical trial in advanced Parkinson's disease in Q4 2025Strengthened balance sheet with recent financingAdvancing innovative POZ Platform across multiple therapeutic modalitiesTwo new seasoned biotech leaders added to the Board of Directors HUNTSVILLE, May 08, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the first quarter ended March 31, 2025, along with recent business highlights. "We are energized by the substantial progress and strengthened foundation
